Literature DB >> 16529136

Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise.

Christopher L Sola1, J Michael Bostwick, Dionne A Hart, Timothy W Lineberry.   

Abstract

Linezolid, a novel antimicrobial with activity against gram-positive bacteria including pathogens resistant to traditional antimicrobials, also inhibits monoamine oxidase. This latter property can cause potentially lethal adverse interactions with antidepressant medications. Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. We review the pharmacology of MAOis and describe 3 clinical situations In which linezolid-selective serotonin inhibitor (SSRI) interactions, actual or potential, figured prominently.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529136     DOI: 10.4065/81.3.330

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

Review 1.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

2.  Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin.

Authors:  T P Lodise; N Patel; A Rivera; L Tristani; V Lazariu; H Vandewall; L A McNutt
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 3.  Serotonin syndrome: take a closer look at the unwell surgical patient.

Authors:  Z S Shaikh; S Krueper; T J Malins
Journal:  Ann R Coll Surg Engl       Date:  2011-11       Impact factor: 1.891

4.  Update on the appropriate use of linezolid in clinical practice.

Authors:  Roberto Manfredi
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.